Fashion Concept GmbH: Jeremy Meeks to conquer fashion world
27.9.2019 14:25:00 EEST | Business Wire | Press release
We are experiencing a time of social and technological revolution. Fashion Concept GmbH is not just a pioneer, it has also been able to sign a deal with one of the icons of the fashion industry, former "hot felon" Jeremy Meeks. Fashion Concept GmbH focuses on the international trade in textiles. By using sustainable materials and promoting investment in new technologies, the company aims to ensure the long-term availability of environmentally-friendly fashion.
The company's goal is to set new standards for sustainability. To reinforce this goal, Fashion Concept has just signed a $15 million deal with Jeremy Meeks to develop his own brand. For Meeks, who has been a regular presence on the catwalk for various fashion designers, this collaboration means a higher profile and a wider audience, because not only will he be a top model, but he will also be marketing his own fashion label.
It is not just this mega deal that is a milestone in Jeremy's career; his private life is also on the upswing. He was recently photographed with a well-known actress. But things are not just on the upswing for Jeremy: Fashion Concept GmbH, with its focus on uniquely innovative and sustainable technologies, is making a bold move with this deal as it seeks to drive forward change in the fashion industry. Fashion Concept aims to expand the growth in fashion and lifestyle brands. Higher revenues are being generated each year on Germany's fashion market, in retail and, in particular, through online business; private investors, too, will soon have the opportunity to benefit from this growth. The profit margins of often up to 30% will be of particular interest for investors.
This is precisely the market segment where Fashion Concept is active. In international trade, the company has seen a growth of almost 300% in its sales over the last two years alone. The company is already making profits in purchasing, since it can access its own production facilities in Turkey. In addition, merchandise such as textiles and accessories from many top manufacturers are being produced and purchased at very favourable conditions. The opportunity to purchase at high volumes allows savings of up to 90% to be achieved.
The company plans to purchase further top textile brands in 2020. This will not only expand its product offerings significantly, it will also have a direct impact on prices.
The group works with numerous distributors, allowing it to be able to choose the most efficient marketing channel for its products at all times. In this way, it can maximise the revenue from the quick sale of its merchandise.
The company does not rely on bank loans, but instead uses subordinated loans, bonds, profit participation rights, and silent partnerships for individuals who can directly benefit from the company's growth with a fixed return, currently at three to five percent.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190927005188/en/
Contact information
Name:Oguzhan Dertli
Tel: 00905392010251
Email:ahmet@fashion-concept.com
Fashion Invest AG
De-Saint-Exupéry-Straße 10
60549 Frankfurt am Main
Tel.: +4969348713577
Email: press@fashion-invest.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 15:08:00 EET | Press release
Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223465174/en/ Under the terms of the multi-year agreement, Quiver will receive an undisclosed advance payment and support for defined research activities along with additional licensing fees granting Angelini Pharma exclusive access to collaboration-generated data during the research term. Quiver is also eligible to receiv
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DISA IL authorized Cyber Exposure Management Platform. The company previously achieved FedRAMP Mo
IQM, a Global Leader for Quantum Computing, to Become the First Listed European Quantum Company, Through Merger with Real Asset Acquisition Corp.23.2.2026 14:49:00 EET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), today announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading provider of quantum computers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223639678/en/ IQM Quantum Computers is going public Headquartered in Finland, IQM is also considering a dual listing that would see the trading of IQM’s ordinary shares on the Helsinki stock exchange, which would be
Organon Enters into Agreement to License MIUDELLA ® , Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device23.2.2026 14:30:00 EET | Press release
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA's alternate supply chain entities and certain other conditions. MIUDELLA, the first hormone-free copper IUD approved in the U.S. in the last 40 years, is complementary to Organon’s commercial capabilities and would further Organon’s commitment to building a portfolio of products that meet women’s diverse reproductive health needs. MIUDELLA was approved by the FDA on February 24, 2025, for the prevention of pregnancy in females of reproductive potential for up to three years and is not yet
Revolutionizing Performance Measurement: Industry-First Methodology for Testing 5G Network Slices Enabled by Ookla and Ericsson23.2.2026 13:00:00 EET | Press release
Ookla®, a global leader in connectivity intelligence, and Ericsson, a world leader in communications technology, demonstrate an innovative solution allowing users to measure and validate 5G network slicing performance. This collaboration marks a major milestone in the 5G-Advanced era, providing a way to validate the Quality of Experience (QoE) essential for the next generation of mobile applications and use cases. Historically, measuring the performance of an individual network slice from a consumer or enterprise device has been a significant technical challenge. Traditional speed tests measure the default internet connection. Through this collaboration, Ookla and Ericsson developed a methodology that enables the Speedtest app to identify and test specific network slices. This breakthrough demonstrates how Service Level Agreements (SLAs) for differentiated services can finally be verified in real-time by both consumers using the Speedtest app and service providers. Crucially, this puts
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom